CIC pulls up govt for ‘evasive’ RTI reply on who created Aarogya Setu – Home Health Choices
Times News NetworkNew Delhi: In a strongly worded order, the…Latest Updates
Hyderabad: Vaccine main Bharat Biotech has entered right into a licensing settlement with the Washington University School of Medicine in St Louis (WashU). The deal has been struck for growing, conducting medical trials, manufacturing and distributing a novel chimp-adenovirus, single dose intranasal vaccine candidate for Covid-19.
As per the pact, Bharat Biotech may have the rights to distribute the vaccine in all international markets, excluding US, Europe and Japan. While the Phase I trials for the vaccine will happen in Saint Louis University’s vaccine & remedy analysis unit, the corporate will take up additional phases of medical trials for the vaccine in India after acquiring approvals. Bharat Biotech will take up giant scale manufacturing of the vaccine at its facility in Hyderabad. It plans to fabricate a couple of billion doses.